Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?
J Clin Oncol
.
2020 May 20;38(15):1645-1647.
doi: 10.1200/JCO.20.00136.
Epub 2020 Feb 25.
Author
Michael A Davies
1
Affiliation
1
Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
PMID:
32097093
PMCID:
PMC7238487
DOI:
10.1200/JCO.20.00136
No abstract available
Publication types
Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Comment
MeSH terms
Humans
Immunotherapy / adverse effects
Melanoma* / drug therapy
Grants and funding
R01 CA187076/CA/NCI NIH HHS/United States
R01 CA193970/CA/NCI NIH HHS/United States
P50 CA221703/CA/NCI NIH HHS/United States
U54 CA224070/CA/NCI NIH HHS/United States
T32 CA009666/CA/NCI NIH HHS/United States